HER2-expressing
Showing 1 - 25 of >10,000
Gynecological Malignancies Trial in Beijing (BL-M07D1)
Not yet recruiting
- Gynecological Malignancies
-
Beijing, Beijing, ChinaCancer Hospital, Chinese Academy of Medical Sciences
Nov 15, 2023
HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification Trial in San Antonio, Fairfax (ORM-5029)
Not yet recruiting
- HER2-positive Breast Cancer
- +3 more
-
San Antonio, Texas
- +1 more
Aug 22, 2022
HER2 Expressing or Mutated Advanced Malignant Solid Tumors Trial in China (GQ1005)
Recruiting
- HER2 Expressing or Mutated Advanced Malignant Solid Tumors
-
Beijing, Beijing, China
- +19 more
Nov 23, 2023
Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer Trial in Boston (Trastuzumab
Not yet recruiting
- Invasive Breast Cancer
- +4 more
- Trastuzumab deruxtecan
- Durvalumab
-
Boston, Massachusetts
- +1 more
Mar 20, 2023
Locally Advanced or Metastatic HER2-Expressing Cancers Trial in Australia, Spain (AMX 818, Pembrolizumab)
Recruiting
- Locally Advanced or Metastatic HER2-Expressing Cancers
-
Melbourne, Australia
- +9 more
Jan 16, 2023
Colorectal Tumors Trial (Pembrolizumab, Disitamab vedotin)
Not yet recruiting
- Colorectal Neoplasms
- Pembrolizumab
- Disitamab vedotin
- (no location specified)
Apr 19, 2022
Advanced Solid Tumor Trial (SHR-4602 for injection)
Not yet recruiting
- Advanced Solid Tumor
- SHR-4602 for injection
- (no location specified)
Apr 6, 2023
Advanced Solid Tumors Trial in Shanghai, Chengdu (SHR-A1811, Fluzoparib Capsule)
Enrolling by invitation
- Advanced Solid Tumors
- SHR-A1811
- Fluzoparib Capsule
-
Shanghai, Shanghai, China
- +1 more
Jun 28, 2022
Endometrial Serous Adenocarcinoma, Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in United States
Recruiting
- Endometrial Serous Adenocarcinoma
- +2 more
- Biopsy
- +3 more
-
Phoenix, Arizona
- +3 more
Feb 2, 2023
Gastric Cancer, HER2-low-expressing Gastric Cancer Trial in Shanghai (Disitamab Vedotin, Toripalimab)
Recruiting
- Gastric Cancer
- HER2-low-expressing Gastric Cancer
- Disitamab Vedotin
- Toripalimab
-
Shanghai, ChinaShanghai East Hospital
Oct 9, 2023
Urothelial Carcinoma Trial (Disitamab Vedotin, radiotherapy)
Not yet recruiting
- Urothelial Carcinoma
- Disitamab Vedotin
- radiotherapy
- (no location specified)
Jun 20, 2023
Bladder Cancer Trial (Disitamab Vedotin for Injection,Penpulimab Injection)
Not yet recruiting
- Bladder Cancer
- Disitamab Vedotin for Injection,Penpulimab Injection
- (no location specified)
Aug 2, 2022
Gynecological Malignancy Trial in Beijing (RC48-ADC)
Recruiting
- Gynecological Malignancy
-
Beijing, Beijing, ChinaChinese Academy of Medical Sciences Cancer Hospital
Jan 6, 2022
HER2-expressing Advanced Solid Tumors Trial (SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor
Not yet recruiting
- HER2-expressing Advanced Solid Tumors
- SHR-A1811 combined with Pyrotinib.
- SHR-A1811 combined with other antitumor therapies
- (no location specified)
Aug 28, 2023
Urothelial Carcinoma, HER2-expressing Trial in Beijing (RC48-ADC, Toripalimab, Gemcitabine)
Not yet recruiting
- Urothelial Carcinoma
- HER2-expressing
- RC48-ADC
- +4 more
-
Beijing, Beijing, China
- +1 more
Apr 2, 2022
Breast Cancer Trial (Disitamab Vedotin+Anlotinib)
Not yet recruiting
- Breast Cancer
- Disitamab Vedotin+Anlotinib
- (no location specified)
Aug 14, 2023
DESTINY Breast Respond HER2-low Europe
Not yet recruiting
- Unresectable Breast Cancer
- +2 more
- Trastuzumab deruxtecan
- (no location specified)
Jul 6, 2023
Her2-positive/Low-expression Urinary and Digestive Tract Tumors Trial in Beijing (BL-M07D1)
Not yet recruiting
- Her2-positive/Low-expression Urinary and Digestive Tract Tumors
-
Beijing, Beijing, ChinaCancer Hospital, Chinese Academy of Medical Sciences
Sep 8, 2023
Chordoma, Breast Cancer, Gastric/Gastroesophageal Junction Cancer Trial in United States (TAEK-VAC-HerBy)
Recruiting
- Chordoma
- +2 more
- TAEK-VAC-HerBy
-
Scottsdale, Arizona
- +8 more
Oct 27, 2022